Take control with Confidante this Sexual Health Week
The prevalence of STIs
More than 30 different bacteria, viruses and parasites known to be transmitted through sexual contact and therefore over 1 million sexually transmitted infections (STIs) are acquired every day worldwide.
As a result the requirement for multiplex diagnostic testing has become increasingly prevalent, as many STIs can co-exist.
Sexual Health Week
Sexual Health Week, which takes place on 24th – 28th September each year, highlights the importance of safe sex. If you have recently entered a new relationship, experienced unprotected sex or are planning a family you may wish to avail of an STI test to determine your current sexual health status and take appropriate corresponding action.
The thought of sexual health testing however can often be nerve-wracking and embarrassing, which is why we offer a home testing kit called Confidante, which enables you to be tested for 10 of the most common STIs from the comfort of your own home.
You can purchase your test kit in complete confidence as transactions are handled safely and securely.
STIs tested with Confidante
|· Chlamydia||· Trichomonas Vaginalis|
|· Gonorrhoea||· Mycoplasma Hominis|
|· Syphilis||· Mycoplasma Genitalium|
|· Herpes Simplex 1||· Ureaplasma Urealyticum|
|· Herpes Simplex 2||· Chancroid|
The process is simple and easy to follow:
- Buy Online
- Register Kit Online
- Collect Sample and Post
- Receive Results
Confidante is specifically designed to be straightforward to use, with all you need included in our discreetly packaged kit. We have made the entire process as convenient as possible with pre-paid envelopes and user-friendly instructions to ensure a simple, hassle-free process.
You will receive your confidential results in 7 working days of posting your sample either via email or telephone depending upon your section on the test order form.
To order your STI kit visit https://www.confidantetest.com/
For further information please contact email@example.com or phone 028 9442 2413
You may have heard of Companion Diagnostics. This type of diagnostic provides information that is essential for the safe and effective use of a corresponding drug or biological product. It can help to stratify groups of patients which will respond safely to a clinical drug trial, and those who may suffer undesirable side effects.
But why are Companion Diagnostics useful?
Randox Biosciences Pharma Relationship Manager Dr Miguel Quesada-González, PhD has the answer.
“As part of my new role, I’ll be supporting drug development and clinical trials. So as a scientist by background (the nature of the beast) I’ve been reading into and researching this incredibly interesting area of science.
“Since Day 1, Companion Diagnostics (CDx) especially caught my eye.
“When it comes to new drug development, either for Pharma or Biotech, there are many benefits of running a CDx. Based on well-acknowledged scientific papers that I have read, and my own personal perception of the current situation, I’d like to summarise and simplify in just 2 bullet points, what I personally believe to be the most important benefits of running a CDx.
“(a) Delivering the right treatment to the right patient at the right time.
“We should never forget that our priority is the health and integrity of patients. It’s been proven that patients who have similar diagnoses very often respond differently to the same treatment. This variability presents a risk in both the efficacy of the treatment and the safety of the patient.
“The development of a drug is already a risky, long and costly process, so wouldn’t you like to avoid the initial high risk by having a good defined target initially?
“(b) Saving time.
“Money is valuable but time even more so. Time is precious and priceless. Once it’s gone, there’s nothing we can do about it!
“The smaller and more targeted the clinical trials are, the less time and resources you’ll be spending. Normally, the CDx is not initiated until a drug has reached the later stages of development, but, actually, if you put the CDx in place at early development stages (preclinical) it presents many advantages because it enables the selected biomarker to be validated and determined before large amounts of resources have been put in place.
“The faster a potential treatment is developed and approved, the more people you can save, cure or simply improve their quality of life.”
For further information on Companion Diagnostics from Randox Biosciences please email us at firstname.lastname@example.org
Chronic Kidney Disease (CKD) is both a cause and a consequence of cardiovascular diseases, and is an increasing burden on global health. As diabetes, obesity and hypertension incidences continue to rise and the world’s population steadily ages, CKD’s prevalence is already estimated to be between 11% and 13% globally for all five KDOQI stages, with a majority in Stage 3 (about 90% of all stages).
With early stages of CKD being asymptomatic and current diagnostic tools (proteinuria determined by albumin to creatinine ratio and decreased renal function estimated from GFR using the CKD-EPI equation) are insufficiently sensitive to detect most cases up to stage 3, it is likely that the true prevalence of CKD is still underestimated. Therefore the need to improve both early diagnostics and overall CKD outcome is all the more critical.
Accordingly, biomarker research has been intense in the field of renal disease for at least 10 years with a number of promising candidates emerging, some now well-known by specialists: Cystatin C, NGAL or KIM-1 for example.
However, further novel biomarkers, assessed in combination using a properly developed multiplex assays can allow superior insight into CKD than what their individual performance could achieve. This also largely stems from selecting the markers that are indicative of complementary mechanisms that contribute to the development of CKD.
When assayed together from a single serum sample and after combinatorial analysis has been applied, these biomarkers can open new avenues in the management of CKD, such as proper diagnosis of the condition from Stage 1, clear differentiation between stages and monitoring of the progression pace of the disease. Early screening of patients at risk of CKD is now within reach and it is expected that its systematic use will have a profound impact on health system economics.
Another area of interest in renal research is Acute Kidney Injury (AKI) which may arise as a result of cardiac surgery and can subsequently lead to CKD. AKI detection is also of significant interest in the field of drug development, where early stage toxicity is still a large cause of new drug marketing withdrawal. Hence selecting and qualifying kidney tissue damage biomarkers, and assembling them into a multiplex panel is a key priority to those involved in early stage clinical trials.
An AKI panel has been worked out using the same principles as those used in the development of the CKD panel: high individual diagnostic value and multiple, independent cellular targets. This panel is now ready for final clinical qualification and will be one of the first of several organ-targeted safety panels aiming to become standard for drug induced toxicity screening.
It is key to the adoption of multiplex testing that proper validation guidelines be published and that careful, matrix-based validation data is made available to potential users. It is essential that multiplexed testing comes to the front line of testing in the field, so it can deliver to its full potential and start translating into public health improvement and cost savings. Technology is ready, let’s make a start!
Dr Claire Huguet
Randox Biosciences – Head of Biomarkers
For further information about kidney disease screening from Randox Biosciences, please contact email@example.com
Almost a year to the day of the tragic death of the “King of Heswall” Tim Cogley, his father will be joined by some of the UK’s best-known sports stars at an event in Liverpool to raise awareness of how lives can be saved through improving access to earlier routine health screening.
On April 9th 2017 Tim, who was only 34-years old, suffered a fatal heart attack due to a genetic condition which could have been managed had it been diagnosed earlier. It spurred his father, Frank Cogley, to set up a charity to raise awareness of the importance of health checks for young people.
He’ll be joined at the free Randox Health Week event in Exchange Station on 11th April by legendary jockey Sir AP McCoy, champion boxer Paul Smith and Olympic sailor Matt McGovern. The public will be invited to join the discussions as well.
Frank said: “It’s been recently reported that at least 12 under-35s die from undiagnosed heart conditions every week in the UK. The current lack of routine screening of 18-40-year olds leaves a gaping chasm in our healthcare provision. With our highly motivated partners, through events like this, we hope to redress this through lifestyle changes and preventative medical programmes. The ‘Tim Cogley Cardiac Screening Foundation’ is committed to delivering positive, action-focused and life-changing programmes. I can’t imagine a legacy more in tune with the generous, kind and supportive person that was Tim!”
This is the second year that Randox Health Week has been held in the city. The areas of mental health and active cities will be explored on days one and two – the 9th and 10th respectively. On each of the mornings, local athletes Franny Norton and Derry Mathews will be putting pupils to the test with a range of sporting activities at LJMU’s Byrom Street campus.
By working with the city’s leading universities – Liverpool John Moores and Liverpool Hope – cutting-edge innovations in healthcare and emerging trends are being shared with a global audience. One such ground-breaking development is a test for prediabetes which is key to tackling the worldwide threat of preventable cases of Type-2 diabetes. It’s something that legendary jockey Sir Anthony McCoy, also taking part in Wednesday’s talk, has first-hand experience of:
“When I got my first test results back that said I had prediabetes, it floored me. I had never imagined that I, someone who had been a professional athlete all of my life, could develop it. It just goes to show that we’re all vulnerable. I only wish it had been around when it could have helped my mum who lived with Type-2 diabetes for many years. As daunting as it was getting the diagnosis, it’s been empowering to very simply make lifestyle changes to reverse it. This needs to be accessible to everyone – it needs to be on the national diabetes screening programme.”
Dr Peter FitzGerald, Managing Director of Randox Health, commented: “The themes we’re focusing on this week are some of the most important global concerns facing us today – mental health, physical activity and showing people the benefits to being proactive about their health, rather than facing the consequences of preventable sickness. You need look no further than Frank Cogley who is working tirelessly to turn his son’s tragic death into a force for good to see how important this is. With the support from AP McCoy and Paul Smith, we hope this event will inspire many people in the city and beyond.”
Tickets are free and can be reserved at www.eventbrite.co.uk/e/randox-health-week-2018-tickets-43648350391
For further information about Randox Health Week, please contact the Randox PR team by email: firstname.lastname@example.org or by phone: 028 9442 2413
Biochip Array Technology is the fundamental component which drives the Randox Evidence Series immunoanalysers. The simultaneous detection of multiple analytes from a single sample allows for a complete patient profile, providing exceptional time, resource and cost savings.
The Evidence Series analysers all carry the Biochip in different applications. In order to gain a better understanding of how it is utilised, the illustrations below demonstrate how adaptable and flexible the technology is across the Evidence Series.
- One strip contains 10 biochips
- Analyser can hold 20 strips
- Can produce a throughput of up to 2640 tests per hour
- Each cassette contains 10 carriers
- Each carrier has 9 wells
- Analyser can hold 4 cassettes at once
- Can produce a throughput of up to 3960 tests per hour
- Analyser holds 1 cartridge
- 1 cartridge contains 9 wells
- Thermoshaker capable of carrying 6 cartridges
- Can produce a throughput of up to 2376 tests per hour
- Analyser holds 1 cartridge
- Cartridge comes pre-loaded with reagents and QC
- Can produce a throughput of up to 132 tests per hour
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities.
For over 30 years, we have been researching and manufacturing market-leading diagnostics products globally. With a mission statement of ‘dedicated to improving health worldwide’ the patient needs are a central focus of everything we do. It is this experience and commitment to improving healthcare that has allowed us to continually improve our product offering and make advancements globally to reach as many people as possible and provide greater diagnostic facilities.
From this experience and commitment to research, we believe we have developed a technology that has changed diagnostic testing forever.
Biochip Array Technology
In 2002, we invented a world first, which changed the landscape of diagnostic testing forever. Biochip Array Technology is a precision multiplex testing platform allowing for the simultaneous quantitative or qualitative detection of a wide range of analytes from a single sample.
Biochip Array Technology uniquely offers immunoassay diagnostic testing for simultaneous multi-analyte biomarker detection. After addition of a single patient sample to the biochip, analytes present in the sample bind to the specific biochip bound ligands. The degree of binding is determined using a chemiluminescent light source and quantified using a Charge Coupled Device (CCD) camera and imaging system.
An individual biochip has up to 49 Discrete Test Regions with each detecting a different biomarker. That means up to 44 tests can be carried out simultaneously, with the additional DTRs being reserved for visual quality control and visual reference; a feature unique to Biochip Array Technology.
The Evidence Series
Having developed this patented technology following £250 million investment in research and development, we needed a platform that allowed Biochip Array Technology capabilities to be showcased. Step forward the Evidence Series. The series includes the Evidence, the Evidence Evolution, the Evidence Investigator and the Evidence MultiSTAT. Each analyser has been designed and built with boundary pushing engineering, to ensure financial, labour and time savings for the end user.
Have a read below of the brief overview of each analyser in the Evidence Series
The world’s first fully automated random-access biochip testing platform, the Evidence Evolution is the world’s most advanced immunoanalyser. With the capability to process up to 2,640 tests per hour, the Evidence Evolution offers complete system integration, as well as the most comprehensive test menu on the market.
As the world’s first Biochip Array Technology system, the Evidence immunoanalyser has revolutionised laboratory screening worldwide. With the capability to process 3,960 tests per hour and a sample capacity of 360, the Evidence is ideal for use in a high throughput laboratory.
The Evidence Investigator is a compact, semi-automated benchtop immunoanalyser that offers efficient and comprehensive testing across a range of applications including clinical diagnostics, molecular, toxicology and food diagnostics. The Evidence Investigator boasts a throughput of up to 2,376 tests per hour, offering efficiency without compromising on accuracy.
The Evidence MultiSTAT is a fully automated immunoanalyser that enables on-site simultaneous detection of up to 44 analytes from a single sample of oral fluid, urine or blood. With a three-step process and results generated in less than 20 minutes, the Evidence MultiSTAT is an ideal solution for those with no knowledge of laboratory procedures and offers a throughput of up to 132 tests per hour.
About the Randox Evidence Series
The Evidence Series is set to revolutionise diagnostic testing forever. Offering unrivalled capabilities across all analysers, we truly believe that the Evidence Series range of immunoassay analysers can meet your diagnostic testing capabilities. For more information on any of the Evidence Series analysers, please visit https://www.randox.com/evidence-series/ or contact us email@example.com.